1996
Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths
1995
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimen